Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease

ACS Chemical Neuroscience

Volumn 4, Issue 2, 2013, Pages 350-360

  Morales Garcia J A ^a   Susin C ^a   Alonso Gil, S ^a   Perez D I ^b   Palomo, V ^b   Perez C ^b   Conde, S ^b   Santos, A ^c   Gil, C ^b   Martinez A ^b   Perez Castillo A ^a  

^a CSIC   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

drug discovery; GSK 3 inhibitors; neuroprotection; Parkinson's disease

Indexed keywords

ALSTERPAULLONE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HETEROCYCLIC COMPOUND; MALEIMIDE DERIVATIVE; NEUROPROTECTIVE AGENT; QUINOLINE DERIVATIVE; SC 001; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG STRUCTURE; DRUG TRANSPORT; ELECTROCONVULSIVE THERAPY; ENZYMATIC ASSAY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MICROGLIA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS;

EID: 84874086124     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300182g     Document Type: Article

References (50)

1. Damier, P., Hirsch, E. C., Agid, Y., and Graybiel, A. M. (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease Brain 122 (Pt 8) 1437-1448
2. Dick, F. D., De Palma, G., Ahmadi, A., Scott, N. W., Prescott, G. J., Bennett, J., Semple, S., Dick, S., Counsell, C., Mozzoni, P., Haites, N., Wettinger, S. B., Mutti, A., Otelea, M., Seaton, A., Soderkvist, P., and Felice, A. (2007) Environmental risk factors for Parkinson's disease and parkinsonism: The Geoparkinson study Occup. Environ. Med. 64, 666-672
3. Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., and Lees, A. J. (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD Neurology 71, 474-480
4. Tanner, C. M. (2003) Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies Adv. Neurol. 91, 133-142
5. Twelves, D., Perkins, K. S., and Counsell, C. (2003) Systematic review of incidence studies of Parkinson's disease Mov. Disord. 18, 19-31
6. Exner, N., Lutz, A. K., Haass, C., and Winklhofer, K. F. (2012) Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences EMBO J. 31, 3038-3062
7. Frank-Cannon, T. C., Tran, T., Ruhn, K. A., Martinez, T. N., Hong, J., Marvin, M., Hartley, M., Trevino, I., O'Brien, D. E., Casey, B., Goldberg, M. S., and Tansey, M. G. (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration J. Neurosci. 28, 10825-10834
8. Barnum, C. J. and Tansey, M. G. (2010) Modeling neuroinflammatory pathogenesis of Parkinson's disease Prog. Brain Res. 184, 113-132
9. Martinez, A., Gil, C., and Perez, D. I. (2011) Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment Int. J. Alzheimer's Dis. 2011 280502
10. Palomo, V., Perez, D. I., Gil, C., and Martinez, A. (2011) The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy Curr. Med. Chem. 18, 3028-3034
11. Perez, D. I., Gil, C., and Martinez, A. (2011) Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases Med. Res. Rev. 31, 924-954
12. Walsh, D. P. and Chang, Y. T. (2006) Chemical genetics Chem. Rev. 106, 2476-2530
13. Ouyang, M. and Shen, X. (2006) Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells J. Neurochem. 97, 234-244
14. Sutachan, J. J., Casas, Z., Albarracin, S. L., Stab, B. R., 2nd, Samudio, I., Gonzalez, J., Morales, L., and Barreto, G. E. (2012) Cellular and molecular mechanisms of antioxidants in Parkinson's disease Nutr. Neurosci. 15, 120-126
15. Morales-Garcia, J. A., Redondo, M., Alonso-Gil, S., Gil, C., Perez, C., Martinez, A., Santos, A., and Perez-Castillo, A. (2011) Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease PLoS One 6 e17240
16. Garrett, A. R., Murray, B. K., Robison, R. A., and O'Neill, K. L. (2010) Measuring antioxidant capacity using the ORAC and TOSC assays Methods Mol. Biol. 594, 251-262
17. Perez, D. I., Palomo, V., Perez, C., Gil, C., Dans, P. D., Luque, F. J., Conde, S., and Martinez, A. (2011) Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds J. Med. Chem. 54, 4042-4056
18. Palomo, V., Perez, D. I., Perez, C., Morales-Garcia, J. A., Soteras, I., Alonso-Gil, S., Encinas, A., Castro, A., Campillo, N. E., Perez Castillo, A., Gil, C., and Martinez, A. (2012) 5-Imino-1,2,4-thiadiazoles: First small molecules as substrate competitive inhibitors of glycogen synthase kinase 3 J. Med. Chem. 55, 1645-1661
19. Palomo, V., Soteras, I., Perez, D. I., Perez, C., Gil, C., Campillo, N. E., and Martinez, A. (2011) Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities J. Med. Chem. 54, 8461-8470
20. Yuskaitis, C. J. and Jope, R. S. (2009) Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity Cell. Signalling 21, 264-273
21. Di, L., Kerns, E. H., Fan, K., McConnell, O. J., and Carter, G. T. (2003) High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 38, 223-232
22. Cardoso, F. L., Brites, D., and Brito, M. A. (2010) Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches Brain Res. Rev. 64, 328-363
23. Blandini, F., Armentero, M. T., and Martignoni, E. (2008) The 6-hydroxydopamine model: News from the past Parkinsonism Relat. Disord. 14 (Suppl 2) S124-129
24. Deumens, R., Blokland, A., and Prickaerts, J. (2002) Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp. Neurol. 175, 303-317
25. Kirik, D., Rosenblad, C., and Bjorklund, A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat Exp. Neurol. 152, 259-277
26. Dutta, G., Zhang, P., and Liu, B. (2008) The lipopolysaccharide Parkinson's disease animal model: Mechanistic studies and drug discovery Fundam. Clin. Pharmacol. 22, 453-464
27. Kim, W. G., Mohney, R. P., Wilson, B., Jeohn, G. H., Liu, B., and Hong, J. S. (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia J. Neurosci. 20, 6309-6316
28. Liu, B., Du, L., and Hong, J. S. (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation J. Pharmacol. Exp. Ther. 293, 607-617
29. McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., and Tansey, M. G. (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease J. Neurosci. 26, 9365-9375
30. Welsh, G. I. and Proud, C. G. (1993) Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B Biochem. J. 294 (Pt 3) 625-629
31. Turenne, G. A. and Price, B. D. (2001) Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity BMC Cell Biol. 2 12
32. Anderton, B. H., Betts, J., Blackstock, W. P., Brion, J. P., Chapman, S., Connell, J., Dayanandan, R., Gallo, J. M., Gibb, G., Hanger, D. P., Hutton, M., Kardalinou, E., Leroy, K., Lovestone, S., Mack, T., Reynolds, C. H., and Van Slegtenhorst, M. (2001) Sites of phosphorylation in tau and factors affecting their regulation Biochem. Soc. Symp. 73-80
33. Doble, B. W. and Woodgett, J. R. (2003) GSK-3: Tricks of the trade for a multi-tasking kinase J. Cell Sci. 116, 1175-1186
34. Frame, S. and Cohen, P. (2001) GSK3 takes centre stage more than 20 years after its discovery Biochem. J. 359, 1-16
35. Jope, R. S. and Roh, M. S. (2006) Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions Curr. Drug Targets 7, 1421-1434
36. Hernandez, F., de Barreda, E. G., Fuster-Matanzo, A., Goni-Oliver, P., Lucas, J. J., and Avila, J. (2009) The role of GSK3 in Alzheimer disease Brain Res. Bull. 80, 248-250
37. Luo, J. (2009) Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy Cancer Lett. 273, 194-200
38. Chen, G., Bower, K. A., Ma, C., Fang, S., Thiele, C. J., and Luo, J. (2004) Glycogen synthase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death FASEB J. 1162-1164
39. Kozikowski, A. P., Gaisina, I. N., Petukhov, P. A., Sridhar, J., King, L. T., Blond, S. Y., Duka, T., Rusnak, M., and Sidhu, A. (2006) Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease ChemMedChem 1, 256-266
40. Wang, W., Yang, Y., Ying, C., Li, W., Ruan, H., Zhu, X., You, Y., Han, Y., Chen, R., Wang, Y., and Li, M. (2007) Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity Neuropharmacology 52, 1678-1684
41. Gimenez-Cassina, A., Lim, F., Cerrato, T., Palomo, G. M., and Diaz-Nido, J. (2009) Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3 J. Biol. Chem. 284, 3001-3011
42. Barone, F. C. and Feuerstein, G. Z. (1999) Inflammatory mediators and stroke: new opportunities for novel therapeutics J. Cereb. Blood Flow Metab. 19, 819-834
43. del Zoppo, G., Ginis, I., Hallenbeck, J. M., Iadecola, C., Wang, X., and Feuerstein, G. Z. (2000) Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia Brain Pathol. 10, 95-112
44. Jope, R. S., Yuskaitis, C. J., and Beurel, E. (2007) Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics Neurochem. Res. 32, 577-595
45. Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H., and Halliday, G. (2010) Missing pieces in the Parkinson's disease puzzle Nat. Med. 16, 653-661
46. Baki, A., Bielik, A., Molnar, L., Szendrei, G., and Keseru, G. M. (2007) A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors Assay Drug Dev. Technol. 5, 75-83
47. Ou, B., Hampsch-Woodill, M., and Prior, R. L. (2001) Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe J. Agric. Food Chem. 49, 4619-4626
48. Luna-Medina, R., Cortes-Canteli, M., Sanchez-Galiano, S., Morales-Garcia, J. A., Martinez, A., Santos, A., and Perez-Castillo, A. (2007) NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders J. Neurosci. 27, 5766-5776
49. Kitamura, Y., Inden, M., Minamino, H., Abe, M., Takata, K., and Taniguchi, T. (2010) The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra Glia 58, 1686-1700
50. aAnastasia, A., Torre, L., de Erausquin, G. A., and Masco, D. H. (2009) Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease J. Neurochem. 109, 755-765